Suppr超能文献

[精神科医生对老年精神分裂症患者抗精神病药物处方的决策与监测]

[Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].

作者信息

Jalenques I, Ortega V, Legrand G, Auclair C

机构信息

Service de psychiatrie de l'adulte A et psychologie médicale, pôle de psychiatrie, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France; UFR médecine, Clermont université, université d'Auvergne Clermont 1, 63001 Clermont-Ferrand, France; Équipe d'accueil 7280, UFR médecine, Clermont université, université d'Auvergne Clermont 1, 63001 Clermont-Ferrand, France; GDR 3557 en psychiatrie, institut de psychiatrie, 7, rue Cabanis, 75014 Paris, France.

Service de psychiatrie de l'adulte A et psychologie médicale, pôle de psychiatrie, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France; UFR médecine, Clermont université, université d'Auvergne Clermont 1, 63001 Clermont-Ferrand, France.

出版信息

Encephale. 2016 Apr;42(2):124-9. doi: 10.1016/j.encep.2015.05.004. Epub 2016 Jan 12.

Abstract

OBJECTIVE

Advancing age entails specific treatment modalities for patients with schizophrenia. The choice of appropriate antipsychotic therapy (AP) and the monitoring of treatment is a major challenge. However, little is known about the real-world prescribing practices of psychiatrists for elderly schizophrenia patients. The aim of this study was to assess prescribing practices and treatment monitoring in elderly schizophrenia patients and whether socio-professional psychiatrists' characteristics are related to their practices.

METHODS

We contacted by mail 190 psychiatrists to take part in an observational survey of their AP prescribing practices for elderly (aged over 65) schizophrenia patients.

RESULTS

The response rate was 44.2%, and of the psychiatrists who replied 75% were treating elderly schizophrenia patients. A second-generation AP (SGAP) was prescribed as first-line of treatment by 87.7% of the psychiatrists. The most frequently used SGAPs were risperidone and olanzapine (respectively preferred by 54.4% and 19.3% of the psychiatrists taking part). At the beginning of treatment, 91.1% of the psychiatrists prescribed a lower dose than for middle-aged patients. Of the psychiatrists taking part, 64.9% prescribed monotherapy; and among these psychiatrists, 65% cited insufficient control of the disease as the reason for their choice, while 48.7% of those who elected not to prescribe combined AP did so in order to limit the side-effects. Of the psychiatrists taking part, 54.4% prescribed long-acting injectable AP (LAAP); better therapeutic compliance and alliance was the main argument in the choice of LAAP given by the psychiatrists taking part who prescribed the drug, whereas the absence of indications and problems of tolerance were arguments against for those who did not. "Personal experience" emerged as the governing factor in the choice of AP. The AP side-effect profile was the main criterion of choice of the AP agent for 3.5% of the psychiatrists taking part, and the most frequently chosen secondary criterion (29.8%). Monitoring of treatment was partly performed according to professional recommendations: pre-treatment and post-prescription assessments of waist circumference and ophthalmological monitoring were very infrequent (8.8 to 18.5%) as were pre-treatment and early post-prescription assessments of prolactinaemia (14.8 to 20.4%); long-term cardiac monitoring was infrequent (43.9%). The psychiatrists taking part whose first-line drug was SGAP were more familiar with professional recommendations than those who prescribed first generation antipsychotic (FGA) drugs (72% as against 14.3%, P=0.006). Of the psychiatrists taking part in the study, 64.9% reported they commonly use professional recommendations. Psychiatrists who declared they commonly use professional recommendations measured pulse rate and blood pressure significantly more often over the long-term than those who did not (74.3% as against 41.2%, P=0.0315). They also measured waist circumference over the long-term significantly more often than psychiatrists who did not commonly use professional recommendations (22.9% as against 0%, P=0.0420). Psychiatrists treating more than ten of these patients yearly measured significantly more often over the long-term pulse rate and blood pressure than those treating fewer patients (80% as against 50%, P=0.0399). Over the long-term monitoring, psychiatrists with a larger number of elderly schizophrenia patients in their care also performed more often fasting blood glucose test, lipid profile and referral for cardiac consultation with ECG (respectively, 95.5% as against 70.8%, P=0.0489; 90.9% as against 58.3%, P=0.0182; 81.8% as against 29.2%, P<0.0001).

CONCLUSIONS

The results of this survey need to be confirmed in a larger population sample. The antipsychotic prescribing practices were broadly in agreement with current recommendations except for the tolerance profile which was not the first element taken into account in the choice of the AP agent. Some clinical and paraclinical medical examinations were carried out infrequently, in particular cardiac monitoring over the long-term, which is essential in this elderly patient population. One important element to emerge from our results was that common use of professional recommendations is associated with better monitoring.

摘要

目的

年龄增长对精神分裂症患者需要采用特定的治疗方式。选择合适的抗精神病药物治疗(AP)及监测治疗情况是一项重大挑战。然而,对于老年精神分裂症患者,精神科医生在现实中的处方习惯却鲜为人知。本研究旨在评估老年精神分裂症患者的处方习惯及治疗监测情况,以及社会职业精神科医生的特征是否与他们的习惯相关。

方法

我们通过邮件联系了190名精神科医生,让他们参与一项关于其对老年(65岁以上)精神分裂症患者AP处方习惯的观察性调查。

结果

回复率为44.2%,在回复的精神科医生中,75%正在治疗老年精神分裂症患者。87.7%的精神科医生将第二代抗精神病药物(SGAP)作为一线治疗药物。最常用的SGAP是利培酮和奥氮平(参与调查的精神科医生中分别有54.4%和19.3%首选)。在治疗开始时,91.1%的精神科医生开出的剂量低于中年患者。参与调查的精神科医生中,64.9%采用单一疗法;在这些精神科医生中,65%将疾病控制不佳作为选择单一疗法的原因,而在选择不联合使用AP的医生中,48.7%是为了限制副作用。参与调查的精神科医生中,54.4%开出长效注射用AP(LAAP);参与调查并开出该药物的精神科医生选择LAAP的主要理由是更好的治疗依从性和医患关系,而未选择的医生则以缺乏适应症和耐受性问题作为反对理由。“个人经验”是选择AP的主导因素。AP的副作用情况是参与调查的3.5%精神科医生选择AP药物的主要标准,也是最常被选择的次要标准(29.8%)。治疗监测部分是按照专业建议进行的:腰围的治疗前和处方后评估以及眼科监测非常少见(8.8%至18.5%),催乳素血症的治疗前和处方后早期评估也很少见(14.8%至20.4%);长期心脏监测很少见(43.9%)。一线药物为SGAP的参与调查精神科医生比使用第一代抗精神病药物(FGA)的医生更熟悉专业建议(72%对14.3%,P = 0.006)。参与研究的精神科医生中,64.9%报告他们通常会使用专业建议。宣称通常使用专业建议的精神科医生比不使用的医生更频繁地长期测量脉搏率和血压(74.3%对41.2%,P = 0.0315)。他们长期测量腰围的频率也显著高于不常使用专业建议的精神科医生(22.9%对0%,P = 0.0420)。每年治疗超过10名此类患者的精神科医生比治疗患者较少的医生更频繁地长期测量脉搏率和血压(80%对50%,P = 0.0399)。在长期监测中,所护理老年精神分裂症患者数量较多的精神科医生也更频繁地进行空腹血糖测试、血脂检查以及进行心电图心脏会诊转诊(分别为95.5%对70.8%,P = 0.0489;90.9%对58.3%,P = 0.0182;81.8%对29.2%,P < 0.0001)。

结论

本次调查结果需要在更大的人群样本中得到证实。抗精神病药物的处方习惯总体上与当前建议一致,但耐受性情况并非选择AP药物时首先考虑的因素。一些临床和辅助临床检查很少进行,特别是长期心脏监测,而这对该老年患者群体至关重要。我们的研究结果中一个重要因素是,通常使用专业建议与更好的监测相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验